


## Data Sheet

<b>Product Name:</b>	Lorediplon
<b>Cat. No.:</b>	CS-5271
<b>CAS No.:</b>	917393-39-6
<b>Molecular Formula:</b>	C <sub>20</sub> H <sub>15</sub> FN <sub>4</sub> O <sub>2</sub> S
<b>Molecular Weight:</b>	394.42
<b>Target:</b>	GABA Receptor
<b>Pathway:</b>	Membrane Transporter/Ion Channel; Neuronal Signaling
<b>Solubility:</b>	DMSO : 100 mg/mL (253.54 mM; Need ultrasonic)



### BIOLOGICAL ACTIVITY:

Lorediplon is a novel non-benzodiazepine, hypnotic drug acting as a GABA<sub>A</sub> receptor modulator, differentially active at the alpha1-subunit, associated with promoting sleep. Target: GABA Lorediplon is a drug for the treatment of insomnia, has been successfully completed with a best-in-class efficacy profile in terms of maintaining sleep and sleep quality, Lorediplon targets GABA<sub>A</sub>. [1] Lorediplon demonstrates a minimum of 10-fold and 6-fold increase in potency (respectively) in the spontaneous motor activation studies. At concentrations of 1.2mg/kg, Lorediplon demonstrates a 57% increased effect on Slow Wave Sleep (SWS), when compared with a placebo.[2]

### References:

[1]. Zisapel N. Current Phase II investigational therapies for insomnia. *Expert Opin Investig Drugs*. 2015 Mar;24(3):401-411.

[2]. Horoszok L, et al. A single-dose, randomized, double-blind, double dummy, placebo and positive-controlled, five-way cross-over study to assess the pharmacodynamic effects of lorediplon in a phase advance model of insomnia in healthy Caucasian adult male subjects. *Hum Psychopharmacol*. 2014 May;29(3):266-273.

### CAIndexNames:

Acetamide, N-[2-fluoro-5-[3-(2-thienylcarbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]-N-methyl-

### SMILES:

CC(N(C1=CC(C2=CC=NC3=C(C(C4=CC=CS4)=O)C=NN23)=CC=C1F)C)=O

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA